Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors

Nicholas Trakul, Christine N. Chang, Jeremy Harris, Christopher Chapman, Aarti Rao, John Shen, Sean Quinlan-Davidson, Edith J. Filion, Heather A. Wakelee, A. Dimitrios Colevas, Richard I. Whyte, Sonja Dieterich, Peter G. Maxim, Dimitre Hristov, Phuoc Tran, Quynh Thu Le, Billy W. Loo, Maximilian Diehn

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose: Current stereotactic ablative radiotherapy (SABR) protocols for lung tumors prescribe a uniform dose regimen irrespective of tumor size. We report the outcomes of a lung tumor volume-adapted SABR dosing strategy. Methods and Materials: We retrospectively reviewed the outcomes in 111 patients with a total of 138 primary or metastatic lung tumors treated by SABR, including local control, regional control, distant metastasis, overall survival, and treatment toxicity. We also performed subset analysis on 83 patients with 97 tumors treated with a volume-adapted dosing strategy in which small tumors (gross tumor volume <12 mL) received single-fraction regimens with biologically effective doses (BED) <100 Gy (total dose, 18-25 Gy) (Group 1), and larger tumors (gross tumor volume ≥12 mL) received multifraction regimens with BED ≥100 Gy (total dose, 50-60 Gy in three to four fractions) (Group 2). Results: The median follow-up time was 13.5 months. Local control for Groups 1 and 2 was 91.4% and 92.5%, respectively (p = 0.24) at 12 months. For primary lung tumors only (excluding metastases), local control was 92.6% and 91.7%, respectively (p = 0.58). Regional control, freedom from distant metastasis, and overall survival did not differ significantly between Groups 1 and 2. Rates of radiation pneumonitis, chest wall toxicity, and esophagitis were low in both groups, but all Grade 3 toxicities developed in Group 2 (p = 0.02). Conclusion: A volume-adapted dosing approach for SABR of lung tumors seems to provide excellent local control for both small- and large-volume tumors and may reduce toxicity.

Original languageEnglish (US)
Pages (from-to)231-237
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume84
Issue number1
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Tumor Burden
lungs
radiation therapy
Radiotherapy
tumors
Lung
Neoplasms
toxicity
metastasis
dosage
Neoplasm Metastasis
Radiation Pneumonitis
Survival
Esophagitis
Thoracic Wall
chest
Control Groups
set theory
grade

Keywords

  • Biologically effective dose
  • Lung cancer
  • Metastases
  • Stereotactic ablative radiotherapy
  • Stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. / Trakul, Nicholas; Chang, Christine N.; Harris, Jeremy; Chapman, Christopher; Rao, Aarti; Shen, John; Quinlan-Davidson, Sean; Filion, Edith J.; Wakelee, Heather A.; Colevas, A. Dimitrios; Whyte, Richard I.; Dieterich, Sonja; Maxim, Peter G.; Hristov, Dimitre; Tran, Phuoc; Le, Quynh Thu; Loo, Billy W.; Diehn, Maximilian.

In: International Journal of Radiation Oncology Biology Physics, Vol. 84, No. 1, 01.09.2012, p. 231-237.

Research output: Contribution to journalArticle

Trakul, N, Chang, CN, Harris, J, Chapman, C, Rao, A, Shen, J, Quinlan-Davidson, S, Filion, EJ, Wakelee, HA, Colevas, AD, Whyte, RI, Dieterich, S, Maxim, PG, Hristov, D, Tran, P, Le, QT, Loo, BW & Diehn, M 2012, 'Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors', International Journal of Radiation Oncology Biology Physics, vol. 84, no. 1, pp. 231-237. https://doi.org/10.1016/j.ijrobp.2011.10.071
Trakul, Nicholas ; Chang, Christine N. ; Harris, Jeremy ; Chapman, Christopher ; Rao, Aarti ; Shen, John ; Quinlan-Davidson, Sean ; Filion, Edith J. ; Wakelee, Heather A. ; Colevas, A. Dimitrios ; Whyte, Richard I. ; Dieterich, Sonja ; Maxim, Peter G. ; Hristov, Dimitre ; Tran, Phuoc ; Le, Quynh Thu ; Loo, Billy W. ; Diehn, Maximilian. / Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. In: International Journal of Radiation Oncology Biology Physics. 2012 ; Vol. 84, No. 1. pp. 231-237.
@article{0134f95e947b477ebbeceb3434cabc0e,
title = "Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors",
abstract = "Purpose: Current stereotactic ablative radiotherapy (SABR) protocols for lung tumors prescribe a uniform dose regimen irrespective of tumor size. We report the outcomes of a lung tumor volume-adapted SABR dosing strategy. Methods and Materials: We retrospectively reviewed the outcomes in 111 patients with a total of 138 primary or metastatic lung tumors treated by SABR, including local control, regional control, distant metastasis, overall survival, and treatment toxicity. We also performed subset analysis on 83 patients with 97 tumors treated with a volume-adapted dosing strategy in which small tumors (gross tumor volume <12 mL) received single-fraction regimens with biologically effective doses (BED) <100 Gy (total dose, 18-25 Gy) (Group 1), and larger tumors (gross tumor volume ≥12 mL) received multifraction regimens with BED ≥100 Gy (total dose, 50-60 Gy in three to four fractions) (Group 2). Results: The median follow-up time was 13.5 months. Local control for Groups 1 and 2 was 91.4{\%} and 92.5{\%}, respectively (p = 0.24) at 12 months. For primary lung tumors only (excluding metastases), local control was 92.6{\%} and 91.7{\%}, respectively (p = 0.58). Regional control, freedom from distant metastasis, and overall survival did not differ significantly between Groups 1 and 2. Rates of radiation pneumonitis, chest wall toxicity, and esophagitis were low in both groups, but all Grade 3 toxicities developed in Group 2 (p = 0.02). Conclusion: A volume-adapted dosing approach for SABR of lung tumors seems to provide excellent local control for both small- and large-volume tumors and may reduce toxicity.",
keywords = "Biologically effective dose, Lung cancer, Metastases, Stereotactic ablative radiotherapy, Stereotactic body radiation therapy",
author = "Nicholas Trakul and Chang, {Christine N.} and Jeremy Harris and Christopher Chapman and Aarti Rao and John Shen and Sean Quinlan-Davidson and Filion, {Edith J.} and Wakelee, {Heather A.} and Colevas, {A. Dimitrios} and Whyte, {Richard I.} and Sonja Dieterich and Maxim, {Peter G.} and Dimitre Hristov and Phuoc Tran and Le, {Quynh Thu} and Loo, {Billy W.} and Maximilian Diehn",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.ijrobp.2011.10.071",
language = "English (US)",
volume = "84",
pages = "231--237",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors

AU - Trakul, Nicholas

AU - Chang, Christine N.

AU - Harris, Jeremy

AU - Chapman, Christopher

AU - Rao, Aarti

AU - Shen, John

AU - Quinlan-Davidson, Sean

AU - Filion, Edith J.

AU - Wakelee, Heather A.

AU - Colevas, A. Dimitrios

AU - Whyte, Richard I.

AU - Dieterich, Sonja

AU - Maxim, Peter G.

AU - Hristov, Dimitre

AU - Tran, Phuoc

AU - Le, Quynh Thu

AU - Loo, Billy W.

AU - Diehn, Maximilian

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Purpose: Current stereotactic ablative radiotherapy (SABR) protocols for lung tumors prescribe a uniform dose regimen irrespective of tumor size. We report the outcomes of a lung tumor volume-adapted SABR dosing strategy. Methods and Materials: We retrospectively reviewed the outcomes in 111 patients with a total of 138 primary or metastatic lung tumors treated by SABR, including local control, regional control, distant metastasis, overall survival, and treatment toxicity. We also performed subset analysis on 83 patients with 97 tumors treated with a volume-adapted dosing strategy in which small tumors (gross tumor volume <12 mL) received single-fraction regimens with biologically effective doses (BED) <100 Gy (total dose, 18-25 Gy) (Group 1), and larger tumors (gross tumor volume ≥12 mL) received multifraction regimens with BED ≥100 Gy (total dose, 50-60 Gy in three to four fractions) (Group 2). Results: The median follow-up time was 13.5 months. Local control for Groups 1 and 2 was 91.4% and 92.5%, respectively (p = 0.24) at 12 months. For primary lung tumors only (excluding metastases), local control was 92.6% and 91.7%, respectively (p = 0.58). Regional control, freedom from distant metastasis, and overall survival did not differ significantly between Groups 1 and 2. Rates of radiation pneumonitis, chest wall toxicity, and esophagitis were low in both groups, but all Grade 3 toxicities developed in Group 2 (p = 0.02). Conclusion: A volume-adapted dosing approach for SABR of lung tumors seems to provide excellent local control for both small- and large-volume tumors and may reduce toxicity.

AB - Purpose: Current stereotactic ablative radiotherapy (SABR) protocols for lung tumors prescribe a uniform dose regimen irrespective of tumor size. We report the outcomes of a lung tumor volume-adapted SABR dosing strategy. Methods and Materials: We retrospectively reviewed the outcomes in 111 patients with a total of 138 primary or metastatic lung tumors treated by SABR, including local control, regional control, distant metastasis, overall survival, and treatment toxicity. We also performed subset analysis on 83 patients with 97 tumors treated with a volume-adapted dosing strategy in which small tumors (gross tumor volume <12 mL) received single-fraction regimens with biologically effective doses (BED) <100 Gy (total dose, 18-25 Gy) (Group 1), and larger tumors (gross tumor volume ≥12 mL) received multifraction regimens with BED ≥100 Gy (total dose, 50-60 Gy in three to four fractions) (Group 2). Results: The median follow-up time was 13.5 months. Local control for Groups 1 and 2 was 91.4% and 92.5%, respectively (p = 0.24) at 12 months. For primary lung tumors only (excluding metastases), local control was 92.6% and 91.7%, respectively (p = 0.58). Regional control, freedom from distant metastasis, and overall survival did not differ significantly between Groups 1 and 2. Rates of radiation pneumonitis, chest wall toxicity, and esophagitis were low in both groups, but all Grade 3 toxicities developed in Group 2 (p = 0.02). Conclusion: A volume-adapted dosing approach for SABR of lung tumors seems to provide excellent local control for both small- and large-volume tumors and may reduce toxicity.

KW - Biologically effective dose

KW - Lung cancer

KW - Metastases

KW - Stereotactic ablative radiotherapy

KW - Stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84865694578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865694578&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2011.10.071

DO - 10.1016/j.ijrobp.2011.10.071

M3 - Article

C2 - 22381907

AN - SCOPUS:84865694578

VL - 84

SP - 231

EP - 237

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -